Octave vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health care clinic network with in-network insurance coverage, San Francisco CA, raised $52M+. Hybrid virtual and in-person therapy with major payer contracts.
About
Octave is a San Francisco, California-based mental health company founded in 2018 that operates a network of mental health clinics offering therapy and psychiatric care with in-network insurance coverage from major carriers. The company has raised over $52 million and has built a hybrid model offering both in-person care at physical clinic locations and virtual therapy, enabling clients to choose the modality that works best for their needs and circumstances.\n\nOctave's business model prioritizes in-network insurance access, negotiating directly with major commercial payers including Blue Cross Blue Shield, Aetna, and Cigna to make therapy financially accessible to patients who have historically faced high out-of-pocket costs or been directed to out-of-network providers. The company handles credentialing, insurance billing, and administrative infrastructure centrally, allowing its therapists and psychiatrists to focus on clinical work rather than paperwork.\n\nThe company has expanded to multiple markets in California and New York, with plans to grow its geographic footprint. Octave serves adults with a range of mental health conditions including anxiety, depression, relationship difficulties, trauma, and life transitions. By offering in-person clinic access alongside telehealth, Octave differentiates from purely virtual mental health platforms and appeals to clients who prefer or require face-to-face care. Octave is part of the emerging category of tech-enabled mental health clinic operators alongside Mindpath Health and Two Chairs.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.